

MD7005/MD7255 - Advanced Injectable Therapies

Advanced Injectable Therapies

View Online



1.
Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein. Textbook of Diabetes [Internet]. John Wiley & Sons, Incorporated; 2016. Available from: <https://ebookcentral-proquest-com.ezproxy3.lib.le.ac.uk/lib/leicester/reader.action?docID=4769056&query=#>
2.
Gururaj Setty S, Crasto W, Jarvis J, Khunti K, Davies MJ. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal*. 2016 Mar;92(1085):152–164.
3.
Daly H, Davies M, Barnett J, Amin S, Gray G, Leonard J, Northern A, Crasto W, Khunti K, Jarvis J. Development of a self-management education module for those with type 2 diabetes on injectable therapies. *Practical Diabetes*. 2015 Oct;32(8):305–310a.
4.
Ajikumar B Aryangat, John E Gerich. Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. *Vascular Health and Risk Management* [Internet]. 2010;6. Available from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860446/>
5.
Ashwell SG, Amiel SA, Bilous RW, Dashora U, Heller SR, Hepburn DA, Shutler SD, Stephens JW, Home PD. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. *Diabetic Medicine*. 2006 Mar;23(3):285–292.

6.

Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. *The Lancet*. 2008 Mar;371(9618):1073-1084.

7.

Carver C. Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes. *The Diabetes Educator*. 2006 Nov 1;32(6):910-917.

8.

Sharon Allard, Caroline Butler, Sue Cradock, Heather Daly, Jemma Edwards, Elizabeth Gilbert. Using Conversation Maps in practice: the UK experience. *Journal of Diabetes Nursing* [Internet]. 2010;14(1). Available from: <http://go.galegroup.com/ps/i.do?id=GALE|A245106172&v=2.1&u=leicester&it=r&p=EAIM&sw=w&asid=fe5329820c5da4ed2dd0a88a5ced5962>

9.

Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. *Diabetes, Obesity and Metabolism*. 2009 Dec;11(12):1153-1162.

10.

Davies MJ, Donnelly R, Barnett AH, Jones S, Nicolay C, Kilcoyne A. Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. *Diabetes, Obesity and Metabolism*. 2009 Dec;11(12):1153-1162.

11.

Funnell MM. Overcoming Barriers to the Initiation of Insulin Therapy. *Clinical Diabetes*. 2007 Jan 1;25(1):36-38.

12.

Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). *Diabetes, Obesity and Metabolism*. 2006 Jan;8(1):58-66.

13.

Gough SCL. A review of human and analogue insulin trials. *Diabetes Research and Clinical Practice*. 2007 Jul;77(1):1-15.

14.

Garber AJ, Ligthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? *Diabetes, Obesity and Metabolism*. 2007 Sep;9(5):630-639.

15.

Heller SR, Colagiuri S, Vaaler S, Wolffenbuttel BHR, Koelendorf K, Friberg HH, Windfeld K, Lindholm A. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. *Diabetic Medicine*. 2004 Jul;21(7):769-775.

16.

Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P. A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. *Diabetes Care*. 2006 Jun 1;29(6):1269-1274.

17.

Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC. Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. *New England Journal of Medicine*. 2007 Oct 25;357(17):1716-1730.

18.

Holman RR, Turner RC. A Practical Guide to Basal and Prandial Insulin Therapy. *Diabetic Medicine*. 1985 Jan;2(1):45–53.

19.

Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzner TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. *Cochrane Database of Systematic Reviews* [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: <http://doi.wiley.com/10.1002/14651858.CD005613.pub3>

20.

Mäkimmattila S, Nikkilä K, Yki-Järvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. *Diabetologia*. 1999 Mar 19;42(4):406–412.

21.

Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. *BMJ*. 1997 May 24;314(7093):1512–1512.

22.

Ismail-Beigi F. Glycemic Management of Type 2 Diabetes Mellitus. *New England Journal of Medicine*. 2012 Apr 5;366(14):1319–1327.

23.

Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2006 Aug 1;29(8):1963–1972.

24.

Marre M, Shaw J, Brändle M, Bebakar WMW, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S. Liraglutide, a once-daily human GLP-1 analogue, added to a

sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabetic Medicine*. 2009 Mar;26(3):268–278.

25.

Hirsch IB, Buse JB, Leahy J, McGill JB, Peters A, Rodbard HW, Rubin RR, Skyler JS, Verderese CA, Riddle MC. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. *Diabetes, Obesity and Metabolism*. 2014 Mar;16(3):206–214.

26.

Srinivasan BT, Davies M. Glycaemic management of type 2 diabetes. *Medicine*. 2014 Dec;42(12):711–717.

27.

Young LA, Buse JB. GLP-1 receptor agonists and basal insulin in type 2 diabetes. *The Lancet*. 2014 Dec;384(9961):2180–2181.

28.

Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Peoples T, Perkins BA, Welsh JB, Willi SM, Wood MA. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. *New England Journal of Medicine*. 2010 Jul 22;363(4):311–320.

29.

Diamant M, Van Gaal L, Stranks S, Northrup J, Cao D, Taylor K, Trautmann M. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet*. 2010 Jun;375(9733):2234–2243.

30.

Gururaj Setty S, Crasto W, Jarvis J, Khunti K, Davies MJ. New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal*. 2016 Mar;92(1085):152–164.

31.

Rosenstock J, Raccach D, Koranyi L, Maffei L, Boka G, Miossec P, Gerich JE. Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). *Diabetes Care*. 2013 Oct 1;36(10):2945–2951.

32.

Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. *The Lancet*. 2016 Nov;388(10057):2254–2263.

33.

Khunti K, Davies M, Majeed A, Thorsted BL, Wolden ML, Paul SK. Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. *Diabetes Care*. 2015 Feb;38(2):316–322.

34.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*. 2015 Jan;38(1):140–149.

35.

Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. *Diabetes, Obesity and Metabolism*. 2017 Feb;

36.

Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. *Diabetes, Obesity and Metabolism*. 2011 Aug;13(8):677–684.

37.

Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. *Diabetes, Obesity and Metabolism*. 2016 Mar;18(3):203–216.

38.

Srinivasan BT, Jarvis J, Khunti K, Davies MJ. Recent advances in the management of type 2 diabetes mellitus: a review. *Postgraduate Medical Journal*. 2008 Oct 1;84(996):524–531.

39.

Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. *Diabetes, Obesity and Metabolism*. 2012 Sep;14(9):780–788.

40.

June James. Safety and insulin: implementation of national guidance at a local level. *Journal of diabetes nursing* [Internet]. Available from: http://le-primo.hosted.exlibrisgroup.com/primo_library/libweb/action/openurl?ctx=&isServicesPage=true&rft.jtitle=Journal+of+Diabetes+Nursing&rft.aufirst=June∓dscnt=2&url_ctx_fmt=null&vid=44UOLE_services_page&rft.aulast=James&institution=44UOLE&url_ver=Z39.88-2004&rft.atitle=Safety+and+insulin%3A+implementation+of+national+guidance+at+a+local+level&dstmp=1488893669239&fromLogin=true

41.

Rorsman P, Renström E. Insulin granule dynamics in pancreatic beta cells. *Diabetologia*. 2003 Aug 1;46(8):1029–1045.

42.

L. Luzi. Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. *American Journal of Physiology - Endocrinology and Metabolism* [Internet]. American Physiological Society; 1989 Aug 1;257(2):E241–E246. Available from: <http://ajpendo.physiology.org/content/257/2/E241>

43.

Luc JC van Loon. Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. *The American Journal of Clinical Nutrition* [Internet]. 2000 Jan 7;72(1):96–105. Available from: <http://ajcn.nutrition.org/content/72/1/96.full>

44.

Menting JG, Whittaker J, Margetts MB, Whittaker LJ, Kong GKW, Smith BJ, Watson CJ, Žáková L, Kletvíková E, Jiráček J, Chan SJ, Steiner DF, Dodson GG, Brzozowski AM, Weiss MA, Ward CW, Lawrence MC. How insulin engages its primary binding site on the insulin receptor. *Nature*. 2013 Jan 9;493(7431):241–245.

45.

Wahren J, Kallas A. Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes? *Diabetes*. 2012 Sep 1;61(9):2228–2229.

46.

Richter B, Neises G. 'Human' insulin versus animal insulin in people with diabetes mellitus. *Cochrane Database of Systematic Reviews* [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: <http://doi.wiley.com/10.1002/14651858.CD003816.pub2>

47.

Crasto W, Jarvis J, Hackett E, Nayyar V, McNally PG, Davies MJ, Lawrence IG. Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. *Postgraduate Medical Journal*. 2009 Apr 1;85(1002):219–222.

48.

Swinnen SG, Simon AC, Holleman F, Hoekstra JB, DeVries JH. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. *Cochrane Database of Systematic Reviews* [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: <http://doi.wiley.com/10.1002/14651858.CD006383.pub2>

49.

Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, Vähätalo M, Virtamo H, Nikkilä K,

Tulokas T, Hulme S, Hardy K, McNulty S, Hänninen J, Levänen H, Lahdenperä S, Lehtonen R, Ryysy L. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. *Diabetologia*. 2006 Mar;49(3):442–451.

50.

Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, Ping L, Ye J, Rosenstock J. Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin. *Diabetes Care*. 2013 Sep;36(9):2489–2496.

51.

Gough SCL, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes. *Diabetes Care*. 2013 Sep;36(9):2536–2542.

52.

Hirsch IB, Buse JB, Leahy J, McGill JB, Peters A, Rodbard HW, Rubin RR, Skyler JS, Verderese CA, Riddle MC. Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. *Diabetes, Obesity and Metabolism*. 2014 Mar;16(3):206–214.

53.

Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstock J, Pinget M, Mathieu C. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. *The Lancet*. 2011 Mar;377(9769):924–931.

54.

Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzner TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. *Cochrane Database of Systematic Reviews* [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 1996. Available from: <http://doi.wiley.com/10.1002/14651858.CD005613.pub3>

55.

Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AYM, Hoogwerf BJ, Rosenstock J. Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. *Annals of Internal Medicine*. 2011 Jan 18;154(2).

56.

Rosenstock J, Jelaska A, Frappin G, Salsali A, Kim G, Woerle HJ, Broedl UC. Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. *Diabetes Care*. 2014 Jul;37(7):1815-1823.

57.

Frandsen CSS, Madsbad S. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. *Diabetic Medicine*. 2014 Nov;31(11):1293-1300.

58.

Hirsch IB, Franek E, Mersebach H, Bardtrum L, Hermansen K. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST T1). *Diabetic Medicine*. 2017 Feb;34(2):167-173.

59.

Rodbard HW, Bode BW, Harris SB, Rose L, Lehmann L, Jarlov H, Thurman J. Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. *Diabetic Medicine*. 2017 Feb;34(2):189-196.

60.

Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. *Diabetologia*. 2008 Mar;51(3):408-416.

61.

Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A. Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. *Diabetes Care*. 2005 Feb 1;28(2):260-265.

62.

Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. *Diabetes Care*. 2005 Jun 1;28(6):1282-1288.

63.

Pickup JC, Reznik Y, Sutton AJ. Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials. *Diabetes Care*. 2017 May;40(5):715-722.

64.

Davies MJ, Leiter LA, Guerci B, Grunberger G, Ampudia-Blasco FJ, Yu C, Stager W, Niemoeller E, Souhami E, Rosenstock J. Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and lixisenatide monocomponents. *Diabetes, Obesity and Metabolism*. 2017 Apr;

65.

Racah D, Huet D, Dib A, Joseph F, Landers B, Escalada J, Schmitt H. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. *Diabetic Medicine*. 2017 Jun 2;

66.

Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, Pratley RE, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. *New England Journal of Medicine*. 2017 Jun 12;

67.

Wang W, Liu H, Xiao S, Liu S, Li X, Yu P. Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Diabetes Therapy*. 2017 Jun 14;

68.

Villani M, de Courten B, Zoungas S. Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine*. 2017 Sep;34(9):1205-1211.

69.

Leelarathna L, Roberts SA, Hindle A, Markakis K, Alam T, Chapman A, Morris J, Urwin A, Jinadev P, Rutter MK. Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. *Diabetic Medicine*. 2017 Oct;34(10):1372-1379.

70.

Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. - PubMed - NCBI [Internet]. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/18715200>

71.

New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes [Internet]. Available from: <http://www.multivu.com/players/English/72762519-novo-nordisk-IDegLira-treatment/>

72.

Anderson B, Funnell M, American Diabetes Association. *The art of empowerment: stories and strategies for diabetes educators*. 2nd ed. Alexandria, Va: American Diabetes Association; 2005.

73.

MacKinnon M. *Providing diabetes care in general practice: a practical guide to integrated care* [Internet]. 4th ed. London: Class; 2002. Available from:

<https://ebookcentral-proquest-com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=581376>

74.

Walker RA, Rodgers J, Diabetes UK. Diabetes: a practical guide to managing your health. Fully revised and updated. London: Dorling Kindersley; 2010.

75.

Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes [Internet]. 4AD. Available from: <https://www.youtube.com/watch?v=AhhWTmEFuag>

76.

Racah D, Huet D, Dib A, Joseph F, Landers B, Escalada J, Schmitt H. Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine. 2017 Sep;34(9):1193-1204.